Related Experiment Videos
Intravenous ofloxacin in severe infections
W Graninger1, E Presterl, B Walzl
1Department of Chemotherapy, University of Vienna, Austria.
Abstract:
The efficacy and tolerance of intravenous ofloxacin was studied in 70 patients suffering from soft tissue infections (n = 33), intra-abdominal abscesses (n = 14), septicaemia (n = 12), pneumonia (n = 9) and brucellosis (n = 2). The average daily dose was 6 mg/kg divided into two doses. Pathogens treated included Enterobacter cloacae (n = 14), Escherichia coli (n = 12), Staphylococcus aureus (n = 13), Pseudomonas aeruginosa (n = 11), Klebsiella pneumoniae (n = 10), Enterococcus faecalis (n = 8) and Streptococcus spp. (n = 5). Most patients had several underlying diseases. Most of the patients had received other antibiotic therapy without success. Clinically, 41% were considered cured, 19% improved and 30% failed to respond. Bacteriologically, pathogens were eradicated in 52.5% and persisted in 22.5%. Adverse reactions included an anaphylactoid reaction, abnormal liver function (n = 13) and insomnia (n = 2). This study suggests that higher doses of ofloxacin may be needed in deep seated infections.
Insights
Intravenous ofloxacin showed moderate efficacy in treating various infections, with 41% clinical cure rates. Higher doses may be necessary for deep-seated infections, despite some adverse effects like abnormal liver function.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Antibiotic resistance necessitates evaluating existing drugs like ofloxacin.
- Intravenous ofloxacin is used for various bacterial infections.
- Previous therapies were unsuccessful in many patients.
Purpose of the Study:
- To assess the efficacy and tolerance of intravenous ofloxacin.
- To evaluate ofloxacin in treating soft tissue infections, intra-abdominal abscesses, septicaemia, pneumonia, and brucellosis.
- To identify optimal dosing for deep-seated infections.
Main Methods:
- A study involving 70 patients with diverse bacterial infections.
- Administered an average daily dose of 6 mg/kg of ofloxacin, divided into two doses.
- Monitored clinical and bacteriological outcomes, as well as adverse reactions.
Main Results:
- Clinical cure was observed in 41% of patients, with 19% showing improvement.
- Bacteriological eradication occurred in 52.5% of cases; pathogens persisted in 22.5%.
- Adverse reactions included abnormal liver function in 13 patients and insomnia in 2.
Conclusions:
- Intravenous ofloxacin demonstrated variable efficacy across different infection types.
- Higher dosages of ofloxacin might be required for effective treatment of deep-seated infections.
- Further research into optimal dosing strategies for ofloxacin is warranted.